Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
Patent 6217866 Issued on April 17, 2001. Estimated Expiration Date: 
April 17, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 17, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMonoclonal antibodies directed to the her2 receptor Patent #: 5770195 Inventors
AssigneeApplicationNo. 487761 filed on 06/07/1995US Classes:424/143.1, Binds receptor424/130.1, IMMUNOGLOBULIN, ANTISERUM, ANTIBODY, OR ANTIBODY FRAGMENT, EXCEPT CONJUGATE OR COMPLEX OF THE SAME WITH NONIMMUNOGLOBULIN MATERIAL424/138.1, Binds expression product or fragment thereof of cancer-related gene (e.g., oncogene, proto-oncogene, etc.)424/141.1, Monoclonal antibody or fragment thereof (i.e., produced by any cloning technology)424/152.1, Binds eukaryotic cell or component thereof or substance produced by said eukaryotic cell424/155.1, Cancer cell424/156.1, Antigen characterized by name or molecular weight530/388.1, Monoclonal530/388.2, Binds microorganism or normal or mutant component or product thereof (e.g., animal cell, cell-surface antigen, secretory product, etc.)530/388.22, Binds receptor (e.g., transferrin receptor, Fc receptor, dihydropyridine receptor, IL-2 receptor, etc.)530/388.8, Binds cancer cell or component or product thereof (e.g., cell-surface antigen, etc.)530/388.85Binds antigen characterized by name or molecular weight (e.g., CEA, NCA, CC glycoprotein, melanoma gp 150 antigen, etc.)ExaminersPrimary: Johnson, Nancy A.Attorney, Agent or FirmInternational ClassesA61K 039/395C07K 016/28 AbstractHybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.Other References
Field of SearchIMMUNOGLOBULIN, ANTISERUM, ANTIBODY, OR ANTIBODY FRAGMENT, EXCEPT CONJUGATE OR COMPLEX OF THE SAME WITH NONIMMUNOGLOBULIN MATERIALBinds expression product or fragment thereof of cancer-related gene (e.g., oncogene, proto-oncogene, etc.) Monoclonal antibody or fragment thereof (i.e., produced by any cloning technology) Binds receptor Binds eukaryotic cell or component thereof or substance produced by said eukaryotic cell Cancer cell Antigen characterized by name or molecular weight Monoclonal Binds microorganism or normal or mutant component or product thereof (e.g., animal cell, cell-surface antigen, secretory product, etc.) Binds receptor (e.g., transferrin receptor, Fc receptor, dihydropyridine receptor, IL-2 receptor, etc.) Binds cancer cell or component or product thereof (e.g., cell-surface antigen, etc.) Binds antigen characterized by name or molecular weight (e.g., CEA, NCA, CC glycoprotein, melanoma gp 150 antigen, etc.) |
| ||||||||||||||
